|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2002-2-28
|
|
pubmed:abstractText |
To assess the efficacy and toxicity of intraresection cavity (131)I-labeled murine antitenascin monoclonal antibody 81C6 and determine its true response rate among patients with newly diagnosed malignant glioma.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:AkabaniGamalG,
pubmed-author:BignerDarell DDD,
pubmed-author:CokgorIlkcanI,
pubmed-author:ColemanR EdwardRE,
pubmed-author:FriedmanAllan HAH,
pubmed-author:FriedmanHenry SHS,
pubmed-author:HerndonJames EJE2nd,
pubmed-author:McLendonRoger ERE,
pubmed-author:PegramCharles NCN,
pubmed-author:ProvenzaleJames MJM,
pubmed-author:QuinnJennifer AJA,
pubmed-author:ReardonDavid ADA,
pubmed-author:RegaladoLorna VLV,
pubmed-author:RichJeremy NJN,
pubmed-author:SampsonJohn HJH,
pubmed-author:ShafmanTimothy DTD,
pubmed-author:WikstrandCarol JCJ,
pubmed-author:WongTerence ZTZ,
pubmed-author:ZalutskyMichael RMR,
pubmed-author:ZhaoXiao-GuangXG
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1389-97
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11870184-Adult,
pubmed-meshheading:11870184-Aged,
pubmed-meshheading:11870184-Antibodies,
pubmed-meshheading:11870184-Antibodies, Monoclonal,
pubmed-meshheading:11870184-Astrocytoma,
pubmed-meshheading:11870184-Brain Neoplasms,
pubmed-meshheading:11870184-Combined Modality Therapy,
pubmed-meshheading:11870184-Female,
pubmed-meshheading:11870184-Glioblastoma,
pubmed-meshheading:11870184-Glioma,
pubmed-meshheading:11870184-Humans,
pubmed-meshheading:11870184-Immunotherapy,
pubmed-meshheading:11870184-Iodine Radioisotopes,
pubmed-meshheading:11870184-Male,
pubmed-meshheading:11870184-Middle Aged,
pubmed-meshheading:11870184-Oligodendroglioma,
pubmed-meshheading:11870184-Survival Rate,
pubmed-meshheading:11870184-Tenascin,
pubmed-meshheading:11870184-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
|
|
pubmed:affiliation |
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA. reard003@mc.duke.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase II
|
